BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferrari R, Bueno H, Chioncel O, Cleland JG, Stough WG, Lettino M, Metra M, Parissis JT, Pinto F, Ponikowski P, Ruschitzka F, Tavazzi L. Acute heart failure: lessons learned, roads ahead: Viewpoint. Eur J Heart Fail 2018;20:842-50. [DOI: 10.1002/ejhf.1169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Dai H, Li H, Wang B, Zhang J, Chen Y, Zhang X, Liu Y, Shang H. Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis. Front Pharmacol 2022;13:677589. [DOI: 10.3389/fphar.2022.677589] [Reference Citation Analysis]
2 Si K, Wei C, Xu L, Zhou Y, Lv W, Dong B, Wang Z, Huang Y, Wang Y, Chen Y. Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications. Front Endocrinol (Lausanne) 2021;12:770815. [PMID: 34867815 DOI: 10.3389/fendo.2021.770815] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Davison BA, Senger S, Sama IE, Koch GG, Mebazaa A, Dickstein K, Samani NJ, Metra M, Anker SD, Cleland JG, Ng LL, Mordi IR, Zannad F, Filippatos GS, Hillege HL, Ponikowski P, van Veldhuisen DJ, Lang CC, van der Meer P, Núñez J, Bayés-Genís A, Edwards C, Voors AA, Cotter G. Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. Eur J Heart Fail 2021;23:43-57. [PMID: 33340221 DOI: 10.1002/ejhf.2077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Kristjánsdóttir I, Thorvaldsen T, Lund LH. Congestion and Diuretic Resistance in Acute or Worsening Heart Failure. Card Fail Rev 2020;6:e25. [PMID: 33042585 DOI: 10.15420/cfr.2019.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Sokolska JM, Sokolski M, Zymliński R, Biegus J, Siwołowski P, Nawrocka-Millward S, Swoboda K, Gajewski P, Jankowska EA, Banasiak W, Ponikowski P. Distinct clinical phenotypes of congestion in acute heart failure: characteristics, treatment response, and outcomes. ESC Heart Fail 2020. [PMID: 32909684 DOI: 10.1002/ehf2.12973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Adamo M, Lombardi CM, Metra M. June 2020 at a glance: focus on COVID-19, quality of life and comorbidities: June 2020 at a glance: focus on COVID-19, quality of life and comorbidities. Eur J Heart Fail 2020;22:917-8. [DOI: 10.1002/ejhf.1515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Guo L, Liu MF, Huang JN, Li JM, Jiang J, Wang JA. Role of interleukin-15 in cardiovascular diseases. J Cell Mol Med 2020;24:7094-101. [PMID: 32406586 DOI: 10.1111/jcmm.15296] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Ferrari R, Fucili A, Rapezzi C. Understanding the results of the PARAGON-HF trial. Eur J Heart Fail 2020;22:1531-5. [PMID: 32212295 DOI: 10.1002/ejhf.1797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shiraishi Y, Kohsaka S, Katsuki T, Harada K, Miyazaki T, Miyamoto T, Matsushita K, Iida K, Takei M, Yamamoto Y, Shindo A, Kitano D, Nagatomo Y, Jimba T, Yamamoto T, Nagao K, Takayama M; for Tokyo CCU Network Scientific Committee. Benefit and harm of intravenous vasodilators across the clinical profile spectrum in acute cardiogenic pulmonary oedema patients. Eur Heart J Acute Cardiovasc Care 2020;9:448-58. [PMID: 31995391 DOI: 10.1177/2048872619891075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ponikowski P, Kirwan BA, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Khintibidze I, Kragten H, Martinez FA, McDonagh T, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Jankowska EA. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. Eur J Heart Fail. 2019;21:1651-1658. [PMID: 31883356 DOI: 10.1002/ejhf.1710] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
11 Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet 2019;393:1034-44. [PMID: 30860029 DOI: 10.1016/S0140-6736(18)31808-7] [Cited by in Crossref: 99] [Cited by in F6Publishing: 123] [Article Influence: 33.0] [Reference Citation Analysis]
12 Bacmeister L, Schwarzl M, Warnke S, Stoffers B, Blankenberg S, Westermann D, Lindner D. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol 2019;114:19. [PMID: 30887214 DOI: 10.1007/s00395-019-0722-5] [Cited by in Crossref: 79] [Cited by in F6Publishing: 132] [Article Influence: 26.3] [Reference Citation Analysis]